BACKGROUND: The brief period of viral replication in recurrent herpes labialis lesions suggests shorter therapeutic regimens are a logical episodic treatment strategy. OBJECTIVE: We sought to assess the efficacy and safety of single-dose and single-day famciclovir treatments. METHODS: In all, 701 randomly assigned patients self-initiated therapy with famciclovir (1500 mg once [single dose] or 750 mg twice a day for 1 day [single day]) or placebo within 1 hour of onset of the prodromal symptoms of an episode of herpes labialis. Lesion healing was monitored by diaries and frequent clinic visits. RESULTS:Median healing times of primary (first to appear) vesicular lesions in the famciclovir single-dose, famciclovir single-day, and placebo groups were 4.4, 4.0, and 6.2 days, respectively. There was no significant difference between the famciclovir regimens. Adverse events in the famciclovir groups were similar to placebo. LIMITATIONS: The active arms of this trial were not directly compared to other antiviral regimens. CONCLUSION: Single-dose famciclovir reduced time to healing of herpes labialis lesions by approximately 2 days compared with placebo.
RCT Entities:
BACKGROUND: The brief period of viral replication in recurrent herpes labialis lesions suggests shorter therapeutic regimens are a logical episodic treatment strategy. OBJECTIVE: We sought to assess the efficacy and safety of single-dose and single-day famciclovir treatments. METHODS: In all, 701 randomly assigned patients self-initiated therapy with famciclovir (1500 mg once [single dose] or 750 mg twice a day for 1 day [single day]) or placebo within 1 hour of onset of the prodromal symptoms of an episode of herpes labialis. Lesion healing was monitored by diaries and frequent clinic visits. RESULTS: Median healing times of primary (first to appear) vesicular lesions in the famciclovir single-dose, famciclovir single-day, and placebo groups were 4.4, 4.0, and 6.2 days, respectively. There was no significant difference between the famciclovir regimens. Adverse events in the famciclovir groups were similar to placebo. LIMITATIONS: The active arms of this trial were not directly compared to other antiviral regimens. CONCLUSION: Single-dose famciclovir reduced time to healing of herpes labialis lesions by approximately 2 days compared with placebo.
Authors: Anthony Cunningham; Paul Griffiths; Peter Leone; Adrian Mindel; Rajul Patel; Lawrence Stanberry; Richard Whitley Journal: J Clin Virol Date: 2011-09-01 Impact factor: 3.168
Authors: X Sáez-Llorens; R Yogev; A Arguedas; A Rodriguez; M G Spigarelli; T De León Castrejón; L Bomgaars; M Roberts; B Abrams; W Zhou; M Looby; G Kaiser; K Hamed Journal: Antimicrob Agents Chemother Date: 2009-03-09 Impact factor: 5.191
Authors: S D Mehta; S Moses; K Agot; W Agingu; C Parker; J O Ndinya-Achola; R C Bailey Journal: Sex Transm Infect Date: 2007-09-12 Impact factor: 3.519
Authors: Lynne M Mofenson; Michael T Brady; Susie P Danner; Kenneth L Dominguez; Rohan Hazra; Edward Handelsman; Peter Havens; Steve Nesheim; Jennifer S Read; Leslie Serchuck; Russell Van Dyke Journal: MMWR Recomm Rep Date: 2009-09-04